Endocyte, Inc. Common Stock
ECYT
ECYT was delisted on the 20th of December, 2018.
104 hedge funds and large institutions have $74.3M invested in Endocyte, Inc. Common Stock in 2015 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 29 increasing their positions, 32 reducing their positions, and 9 closing their positions.
67% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 9
6% more funds holding
Funds holding: 98 → 104 (+6)
2% less call options, than puts
Call options by funds: $661K | Put options by funds: $672K
9% less repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 32
13% less capital invested
Capital invested by funds: $85.5M → $74.3M (-$11.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$7.1M |
| 2 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$722K |
| 3 |
Morgan Stanley
New York
|
+$562K |
| 4 |
Axa
Paris,
France
|
+$466K |
| 5 |
Millennium Management
New York
|
+$375K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NI
Numeric Investors
Boston,
Massachusetts
|
-$3.18M |
| 2 |
Renaissance Technologies
New York
|
-$1.64M |
| 3 |
HCMT
Highland Capital Management (Texas)
Dallas,
Texas
|
-$1.49M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.26M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1.11M |
ECYT Hedge Fund Activity: Q3 2015 in Review
104 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Endocyte, Inc. Common Stock (ECYT) for Q3 2015, worth a combined $74.3M — down 13% from $85.5M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new ECYT positions and 9 closed out — a net gain of 6 holders — while 29 added to existing stakes and 32 trimmed.
The largest buyer was Baker Bros. Advisors, opening a new position worth an estimated $7.1M. The largest seller was Numeric Investors, cutting an estimated $3.18M.
- 104 institutional investors held Endocyte, Inc. Common Stock (ECYT) as of Q3 2015, up from 98 in Q2 2015.
- Funds reported $74.3M of Endocyte, Inc. Common Stock stock for Q3 2015, down 13% quarter-over-quarter.
- 15 funds opened new Endocyte, Inc. Common Stock positions in Q3 2015 and 9 closed out, a net change of +6 holders.
- The largest Endocyte, Inc. Common Stock buyer in Q3 2015 was Baker Bros. Advisors, an estimated $7.1M added.
- The largest Endocyte, Inc. Common Stock seller in Q3 2015 was Numeric Investors, an estimated $3.18M sold.
Based on aggregated 13F filings for Q3 2015.